For the twelve months ended Jun 30, 2026, Mangoceuticals Inc. reported $315.2K of revenue and -$15.10M of net income.
MGRX revenue was $68.8K in fiscal Q2 2026 (ended Jun 30, 2026), down 59.1% from a year earlier and up 1.3% from the prior quarter. For the full fiscal 2025 it was $456.0K, down 26.0% from fiscal 2024. It rose in 1 of the last 3 fiscal years.
MGRX net income was -$1.31M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.42M a year earlier. For the full fiscal 2025 it was -$20.64M, compared with -$8.71M in fiscal 2024.
MGRX diluted EPS was -$0.09 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$2.17.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $456.0K | $615.9K | $731.5K | $8.9K |
| Cost of revenue | $54.4K | $93.3K | $154.9K | $4.1K |
| Gross profit | $250.4K | $380.0K | $431.5K | $4.8K |
| Selling, general and admin | $3.76M | $3.00M | $3.32M | $1.64M |
| Operating income | -$18.03M | -$7.97M | -$9.22M | -$1.99M |
| Interest expense | $103.5K | $13.7K | -$6.5K | $6.5K |
| Pre-tax income | -$20.64M | -$8.71M | -$9.21M | -$2.00M |
| Net income | -$20.64M | -$8.71M | -$9.21M | -$2.00M |
| EPS, basic | -$2.17 | -$4.80 | -$8.58 | -$2.85 |
| EPS, diluted | -$2.17 | -$4.80 | -$8.58 | -$2.85 |
| Diluted shares | 10.1M | 2.0M | 1.1M | 719,872.2 |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $1.49M | $58.7K | $739.0K | $682.9K |
| Inventory | - | - | $18.5K | - |
| Current assets | $1.55M | $75.6K | $835.4K | $694.6K |
| Total assets | $16.09M | $15.37M | $1.05M | $1.00M |
| Current liabilities | $890.6K | $1.43M | $211.1K | $260.6K |
| Total debt | - | $0 | $0 | $78.3K |
| Total liabilities | $890.6K | $1.43M | $276.0K | $389.3K |
| Shareholders' equity | $15.20M | $13.95M | $774.8K | $614.0K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$5.85M | -$4.86M | -$7.00M | -$1.35M |
| Capital expenditures | - | - | $3.5K | $43.1K |
| Free cash flow | - | - | -$7.00M | -$1.39M |
| Investing cash flow | - | $65.0K | -$3.5K | -$43.1K |
| Financing cash flow | $7.27M | $4.13M | $7.06M | $2.05M |
| Stock-based compensation | $1.17M | $248.7K | $624.5K | $234.1K |
| Depreciation and amortization | - | $9.9K | $24.9K | - |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | -26.0% | -15.8% | 8083.2% | - |
| Gross margin | 54.9% | 61.7% | 59.0% | 54.3% |
| Operating margin | -3954.3% | -1294.4% | -1260.3% | -22279.7% |
| Net margin | -4526.8% | -1413.6% | -1259.4% | -22352.1% |
| Free cash flow margin | - | - | -957.1% | -15545.6% |
| Return on equity | -135.8% | -62.4% | -1189.1% | -325.4% |
| Return on assets | -128.3% | -56.6% | -876.7% | -199.2% |
| Current ratio | 1.74 | 0.05 | 3.96 | 2.67 |
| Debt to equity | - | 0.00 | 0.00 | 0.13 |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.8K | $67.9K | $94.4K | $84.2K | $168.1K | $109.3K | $105.2K | $133.4K | $163.2K | $214.1K | $244.4K | $245.2K |
| Cost of revenue | $10.4K | $8.2K | $8.5K | $2.4K | $18.8K | $24.7K | $21.3K | $21.5K | $29.7K | $20.8K | $53.4K | $52.2K |
| Gross profit | $44.2K | $29.0K | $47.5K | $50.9K | $89.9K | $62.1K | $80.1K | $82.7K | $69.8K | $147.4K | $142.6K | $144.6K |
| Selling, general and admin | $256.1K | $1.05M | $657.2K | $311.4K | $1.25M | $1.54M | $854.1K | $523.9K | $850.7K | $772.0K | $822.8K | $545.0K |
| Operating income | -$1.03M | -$3.13M | -$367.7K | -$7.54M | -$5.27M | -$4.58M | -$1.68M | -$1.76M | -$2.17M | -$2.37M | -$2.57M | -$1.80M |
| Interest expense | - | - | $19.7K | $75.8K | $21.7K | -$13.7K | - | - | - | - | $0 | $0 |
| Pre-tax income | -$1.31M | -$3.40M | -$2.77M | -$7.62M | -$5.42M | -$4.84M | -$1.95M | -$2.00M | -$2.39M | -$2.37M | -$2.57M | -$1.80M |
| Net income | -$1.31M | -$3.40M | -$2.77M | -$7.62M | -$5.42M | -$4.84M | -$1.95M | -$2.00M | -$2.39M | -$2.37M | -$2.57M | -$1.80M |
| EPS, basic | -$0.09 | -$0.22 | - | -$0.69 | -$0.57 | -$1.12 | - | -$1.14 | -$1.37 | -$1.50 | - | -$1.70 |
| EPS, diluted | -$0.09 | -$0.22 | - | -$0.69 | -$0.57 | -$1.12 | - | -$1.14 | -$1.37 | -$1.50 | - | -$1.70 |
| Diluted shares | 17.1M | 16.5M | - | 11.5M | 10.0M | 4.6M | - | 2.0M | 1.7M | 1.6M | - | 1.1M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $228.7K | $174.6K | $1.49M | $481.3K | $101.0K | $76.5K | $58.7K | $73.9K | $490.2K | $15.3K | $739.0K | $1.24M |
| Inventory | - | - | - | - | - | - | - | $13.2K | $14.0K | $14.5K | $18.5K | $21.6K |
| Current assets | $245.7K | $212.5K | $1.55M | $598.2K | $118.0K | $176.7K | $75.6K | $104.1K | $517.6K | $89.8K | $835.4K | $1.34M |
| Total assets | $14.17M | $14.45M | $16.09M | $16.53M | $20.84M | $21.75M | $15.37M | $14.79M | $15.24M | $301.4K | $1.05M | $1.60M |
| Current liabilities | $1.40M | $737.6K | $890.6K | $804.3K | $1.60M | $1.50M | $1.43M | $1.39M | $1.38M | $1.21M | $211.1K | $159.2K |
| Total debt | - | - | - | - | - | $0 | $0 | $0 | $0 | - | $0 | - |
| Total liabilities | $1.65M | $974.6K | $890.6K | $804.3K | $1.60M | $1.50M | $1.43M | $1.40M | $1.41M | $1.26M | $276.0K | $240.7K |
| Shareholders' equity | $12.53M | $13.47M | $15.20M | $15.73M | $19.24M | $20.25M | $13.95M | $13.83M | $13.83M | -$958.5K | $774.8K | $1.35M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$260.5K | -$1.31M | -$1.08M | -$1.24M | -$1.26M | -$2.27M | -$1.13M | -$1.17M | -$1.58M | -$991.1K | -$1.70M | -$1.71M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$1.70M | -$1.71M |
| Investing cash flow | - | - | - | - | - | - | $0 | $0 | - | - | $0 | $0 |
| Financing cash flow | - | - | $2.08M | $1.62M | $1.28M | $2.29M | $1.12M | $750.0K | $1.99M | $267.5K | $1.20M | $0 |
| Stock-based compensation | $12.4K | $1.09M | -$33.5K | $1.10M | $51.0K | $51.0K | $51.0K | $108.8K | $51.0K | $38.0K | $429.1K | $66.8K |
| Depreciation and amortization | - | - | - | $256 | $252 | $250 | $255 | $3.5K | $0 | $6.2K | $6.3K | $12.5K |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -59.1% | -37.9% | -10.3% | -36.8% | 3.0% | -48.9% | -56.9% | -45.6% | 15.5% | 112.6% | - | - |
| Gross margin | 64.3% | 42.7% | 50.3% | 60.4% | 53.5% | 56.8% | 76.1% | 62.0% | 42.8% | 68.8% | 58.3% | 59.0% |
| Operating margin | -1502.5% | -4606.8% | -389.7% | -8953.5% | -3134.0% | -4186.8% | -1594.0% | -1318.2% | -1329.1% | -1105.9% | -1050.9% | -734.0% |
| Net margin | -1909.1% | -5014.6% | -2935.1% | -9042.8% | -3221.6% | -4427.5% | -1851.2% | -1499.0% | -1465.4% | -1105.9% | -1050.9% | -734.0% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - | -694.7% | -697.8% |
| Current ratio | 0.18 | 0.29 | 1.74 | 0.74 | 0.07 | 0.12 | 0.05 | 0.07 | 0.38 | 0.07 | 3.96 | 8.44 |
| Debt to equity | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - |
Source: XBRL data Mangoceuticals Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Nov 14, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MGRX | $315.2K | -38.9% | -$15.10M | -4791.3% | $4.2M |
| FMS | €19.63B | +1.5% | €978.37M | 5.0% | $13.07B |
| DVA | $14.17B | +6.4% | $920.08M | 6.5% | $12.04B |
| SHC | $1.23B | +6.9% | $173.47M | 14.1% | $4.57B |
| PGNY | $1.34B | +5.5% | $91.02M | 6.8% | $2.67B |
| AGL | $6.00B | +2.0% | -$87.10M | -1.5% | $1.90B |
| VMD | $310.37M | +21.8% | $15.89M | 5.1% | $346.0M |
| CCEL | $31.13M | -2.0% | -$1.95M | -6.2% | $39.4M |